← All indications
Tongue Neoplasms
Tumors or cancer of the TONGUE.
Drugs by status
Phase 3 trials (5)
Phase 2 trials (33)
- F 18-fluoroazomycin arabinoside
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- saracatinib
- allogeneic natural killer cells
- mk-1775
- sorafenib
- bowman-birk inhibitor
- irinotecan
- temsirolimus
- echinacea
- paclitaxel
- lapatinib
- epidermal growth factor
- autologous natural killer cells
- ixabepilone
- buparlisib
- porfimer
- methylene blue
- celecoxib
- sirolimus
- cetuximab
- beractant
- dasatinib
- bortezomib
- vorinostat
- cediranib
- erlotinib
- vaccinium myrtillus
- macleaya cordata
- recombinant adenoviral human p53 gene
- +3 more
Phase 1 trials (9)
Organizations
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (20)
- HealthCare Global Enterprise Ltd.
- National Institute of Dental and Craniofacial Research (NIDCR)
- Cornell University
- Eastern Cooperative Oncology Group
- Temple University
- Ohio State University
- Southwest Oncology Group
- Stanford University
- Tata Memorial Hospital
- University of South Florida
- University of Toronto
- University of Virginia
- University of California, Irvine
- University of Chicago
- Jinan University
- University of Texas at Houston
- State University of New York, Buffalo
- National Comprehensive Cancer Network
- Shenzhen Hank Bioengineering Institute
- Klus Pharma Inc.
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (4)